Domain Therapeutics, XOMA to jointly evaluate DTect-All to identify allosteric ... News-Medical.net XOMA, a California based U.S. public company, focuses its research on allosteric modulation which offers opportunities for new classes of therapeutic antibodies to treat a wide range of human diseases. Domain Therapeutics has extensive expertise in ... Domain, Xoma Make GPCR-Focused Pact |
